Insights - With the release of its full-year ’13 and Q4 financials on Thursday, Alexion Pharmaceuticals (ALXN) beat on both earnings and revenue, now guiding for 2014 … Continue Reading
Read nowResearch - Update from Friday, January 31st at 9:45 AM ET Today the company revealed that it’s selling 5.76M shares at $21. What would have originally been … Continue Reading
PremiumResearch - Ironwood Pharmaceuticals (IRWD) reported financial results for the fourth quarter and full year 2013 on Tuesday morning. We’re interested primarily for the read-through on Synergy Pharmaceuticals … Continue Reading
Read nowInterviews - Sarepta Therapeutics (SRPT) had a tumultous year, reaching an all-time high of $55.00 last October before tumbling to lows under $13.00 when the U.S. FDA suggested that the company would need to … Continue Reading
Read nowInsights - Retrophin, Inc. (RTRX) priced a recently announced secondary stock offering at $8.50 per share Friday morning, in-line with Thursday’s close. We’ve been watching RTRX for … Continue Reading
PremiumResearch - Shares of Sarepta Therapeutics (SRPT) have been under pressure this week following a downgrade and ‘Sell’ rating from Citigroup, with a $13 price target. Recall … Continue Reading
PremiumResearch - Durect (DRRX) on Tuesday announced an agreement with Impax Laboratories (IPXL) for the exclusive worldwide rights to develop and commercialize ELADUR, Durect’s investigational transdermal bupivacaine … Continue Reading
Premium
